CD274 and neoplasm: Radiomics has shown its ability to assess the biological features of tumoral and peritumoral tissues, including local immune characteristics, such as evaluating the presence of tumor-infiltrating immune cells (CD8+, Th1 or Th2 cells) or PD-L1 expression, suggesting its capacity to play a role in the selection of patients who are more likely to respond to immunotherapy [14,15,16].